About The Study: This randomized clinical trial demonstrates the potential clinical utility of plozasiran, an investigational APOC3-targeted small interfering–RNA drug, to reduce triglyceride level in patients with severe hypertriglyceridemia. Additional studies will be required to determine whether plozasiran favorably modulates the risk of severe hypertriglyceridemia-associated complications.
Authors: Daniel Gaudet, M.D., Ph.D., of the Université de Montréal, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.0959)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the American College of Cardiology’s Annual Scientific Session.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.0959?guestAccessKey=0ae3b504-dfb6-4e89-8883-c74f4f743edf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040724
JAMA Cardiology